{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:12:04Z","timestamp":1787314324873,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The only treatment tested for growth hormone receptor (GHR) defective Laron Syndrome (LS) is injections of recombinant insulin-like-growth factor 1 (rhIGF1). The response is suboptimal and associated with progressive obesity. In this study, we treated 4\u20135-week-old Laron dwarf mice (GHR\u2212\/\u2212) with an adeno-associated virus expressing murine GHR (AAV-GHR) injection at a dose of 4\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    vector genome per mouse. Serum growth hormone (GH) levels decreased, and GH-responsive IGF1, IGF binding protein 3 (IGFBP3) and acid labile subunit (ALS) increased. There was a significant but limited increase in body weight and length, similar to the response to rhIGF1 treatment in LS patients. All the major organs increased in weight except the brain. Our study is the first to use gene therapy to treat GH-receptor deficiency. We propose that gene therapy with AAV-GHR may eventually be useful for the treatment of human LS.\n                  <\/jats:p>","DOI":"10.1038\/s41434-022-00313-w","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T02:03:15Z","timestamp":1643680995000},"page":"346-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-6345","authenticated-orcid":false,"given":"Kian Chuan","family":"Sia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9672-0306","authenticated-orcid":false,"given":"Shu Uin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-0150","authenticated-orcid":false,"given":"Siti Humairah","family":"Mohd Rodhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2177","authenticated-orcid":false,"given":"John J.","family":"Kopchick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-1185","authenticated-orcid":false,"given":"Kok Onn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"313_CR1","first-page":"152","volume":"2","author":"Z Laron","year":"1966","unstructured":"Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone-a new inborn error of metabolism? Isr J Med Sci. 1966;2:152\u20135.","journal-title":"Isr J Med Sci"},{"key":"313_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1210\/jc.2003-031033","volume":"89","author":"Z Laron","year":"2004","unstructured":"Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004;89:1031\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"313_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11154-020-09595-0","volume":"22","author":"Z Laron","year":"2021","unstructured":"Laron Z, Werner H. Laron syndrome \u2013 a historical perspective. Rev Endocr Metab Disord. 2021;22:31\u201341. https:\/\/doi.org\/10.1007\/s11154-020-09595-0","journal-title":"Rev Endocr Metab Disord"},{"key":"313_CR4","first-page":"629","volume":"82","author":"J Guevara-Aguirre","year":"1997","unstructured":"Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency 1. J Clin Endocrinol Metab. 1997;82:629\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"313_CR5","first-page":"128","volume":"51","author":"MB Ranke","year":"1999","unstructured":"Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res. 1999;51:128\u201334.","journal-title":"Horm Res"},{"key":"313_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1210\/jc.2006-1610","volume":"92","author":"SD Chernausek","year":"2007","unstructured":"Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92:902\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"313_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1651-2227.1993.tb12918.x","volume":"82","author":"A Grahnen","year":"1993","unstructured":"Grahnen A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Int J Paediatr. 1993;82:9\u201313. Suppl.","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"313_CR8","first-page":"801","volume":"18","author":"S Rajaram","year":"1997","unstructured":"Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions*. Endocr Rev. 1997;18:801\u201331.","journal-title":"Endocr Rev"},{"key":"313_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fendo.2018.00117","volume":"9","author":"JB Allard","year":"2018","unstructured":"Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol. 2018;9:117.","journal-title":"Front Endocrinol"},{"key":"313_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1515\/JPEM.1995.8.3.149","volume":"8","author":"B Klinger","year":"1995","unstructured":"Klinger B, Laron Z. Three year IGF-I treatment of children with laron syndrome. J Pediatr Endocrinol Metab. 1995;8:149\u201358.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"313_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1517\/21678707.2014.912581","volume":"2","author":"Z Laron","year":"2014","unstructured":"Laron Z. Emerging treatment options for patients with Laron syndrome. Expert Opinion on Orphan Drugs. 2014;2:681\u201394. https:\/\/doi.org\/10.1517\/21678707.2014.912581","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"313_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4158\/EP15939.RA","volume":"21","author":"Z Laron","year":"2015","unstructured":"Laron Z. Lessons from 50 years of study of laron syndrome. Endocr Pract. 2015;21:1395\u2013402.","journal-title":"Endocr Pract"},{"key":"313_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ghir.2015.07.007","volume":"28","author":"Z Laron","year":"2016","unstructured":"Laron Z. Epilogue: the future of Laron syndrome - the need for changes. Growth Horm IGF Res. 2016;28:79\u201380.","journal-title":"Growth Horm IGF Res"},{"key":"313_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/EJE-20-0325","volume":"184","author":"P Bang","year":"2021","unstructured":"Bang P, Woelfle J, Perrot V, Sert C, Polak M. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome. Eur J Endocrinol. 2021;184:267\u201376.","journal-title":"Eur J Endocrinol"},{"key":"313_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464\u201388.","journal-title":"Mol Ther"},{"key":"313_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9","journal-title":"Nat Rev Drug Discov"},{"key":"313_CR17","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, Ragni MV, Rasko JEJ, Raffini LJ, Samelson-Jones BJ, Ozelo M, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28:2073\u201382.","journal-title":"Mol Ther"},{"key":"313_CR18","doi-asserted-by":"publisher","first-page":"13215","DOI":"10.1073\/pnas.94.24.13215","volume":"94","author":"Y Zhou","year":"1997","unstructured":"Zhou Y, Xu BC, Maheshwari HG, Li H, Reed M, Lozykowski M, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor\/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94:13215\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"313_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1566523216666160122113958","volume":"16","author":"G Shu Uin","year":"2016","unstructured":"Shu Uin G, Maria N, Zhen Ying F, Kok Onn L, Kian Chuan S, Amit, et al. Correction of murine diabetic hyperglycaemia with a single systemic administration of an AAV2\/8 vector containing a novel codon optimized human insulin gene. Curr Gene Ther. 2016;16:65\u201372.","journal-title":"Curr Gene Ther"},{"key":"313_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/hum.2014.052","volume":"26","author":"M Della Peruta","year":"2015","unstructured":"Della Peruta M, Badar A, Rosales C, Chokshi S, Kia A, Nathwani D, et al. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Hum Gene Ther. 2015;26:94\u2013103.","journal-title":"Hum Gene Ther"},{"key":"313_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.celrep.2012.08.021","volume":"2","author":"X Jing","year":"2012","unstructured":"Jing X, Miyajima M, Sawada T, Chen Q, Iida K, Furushima K, et al. Crosstalk of humoral and cell-cell contact-mediated signals in postnatal body growth. Cell Rep. 2012;2:652\u201365.","journal-title":"Cell Rep"},{"key":"313_CR22","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/cells9112474","volume":"9","author":"KC Sia","year":"2020","unstructured":"Sia KC, Fu ZY, Calne RY, Nathwani AC, Lee KO, Gan SU. Modification of a constitutive to glucose-responsive liverspecific promoter resulted in increased efficacy of adeno-associated virus serotype 8-insulin gene therapy of diabetic mice. Cells. 2020;9:2474.","journal-title":"Cells."},{"key":"313_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973\u201385.","journal-title":"Gene Ther"},{"key":"313_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2011.104","volume":"23","author":"P Fagone","year":"2012","unstructured":"Fagone P, Fraser Wright J, Nathwani AC, Nienhuis AW, Davidoff AM, Gray JT. Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Hum Gene Ther Methods. 2012;23:1\u20137.","journal-title":"Hum Gene Ther Methods"},{"key":"313_CR25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1210\/jc.2013-3060","volume":"99","author":"N Friedrich","year":"2014","unstructured":"Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (igfbp-3) and the igf-i to igfbp-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675\u201386.","journal-title":"J Clin Endocrinol Metab"},{"key":"313_CR26","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","volume":"121","author":"J McIntosh","year":"2013","unstructured":"McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121:3335\u201344.","journal-title":"Blood."},{"key":"313_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41434-018-0052-5","volume":"26","author":"A Recino","year":"2019","unstructured":"Recino A, Gan SU, Sia KC, Sawyer Y, Trendell J, Kay R, et al. Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2\/8-mediated insulin gene therapy in NOD mice. Gene Ther. 2019;26:40\u201356.","journal-title":"Gene Ther"},{"key":"313_CR28","doi-asserted-by":"publisher","first-page":"e3067","DOI":"10.1002\/jgm.3067","volume":"21","author":"SU Gan","year":"2019","unstructured":"Gan SU, Fu Z, Sia KC, Kon OL, Calne R, Lee KO. Development of a liver-specific Tet-off AAV8 vector for improved safety of insulin gene therapy for diabetes. J Gene Med. 2019;21:e3067.","journal-title":"J Gene Med"},{"key":"313_CR29","doi-asserted-by":"publisher","first-page":"13331","DOI":"10.1073\/pnas.0600181104","volume":"104","author":"BL Conway-Campbell","year":"2007","unstructured":"Conway-Campbell BL, Jong WW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, et al. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA. 2007;104:13331\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"313_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000371798","volume":"83","author":"P Bang","year":"2015","unstructured":"Bang P, Polak M, Woelfle J, Houchard A. Effectiveness and safety of rhIGF-1 therapy in children: the European increlex\u00ae growth forum database experience on behalf of the EU IGFD registry study group. Horm Res Paediatr. 2015;83:345\u201357.","journal-title":"Horm Res Paediatr"},{"key":"313_CR31","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","volume":"75","author":"H Nakai","year":"2001","unstructured":"Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75:6969\u201376.","journal-title":"J Virol"},{"key":"313_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317\u201334.","journal-title":"BioDrugs."},{"key":"313_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1677\/joe.1.06657","volume":"189","author":"S Yakar","year":"2006","unstructured":"Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol. 2006;189:289\u201399.","journal-title":"J Endocrinol"},{"key":"313_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2012.08.028","volume":"165","author":"G Luca","year":"2013","unstructured":"Luca G, Calvitti M, Mancuso F, Falabella G, Arato I, Bellucci C, et al. Reversal of experimental Laron Syndrome by xenotransplantation of microencapsulated porcine Sertoli cells. J Control Release. 2013;165:75\u201381.","journal-title":"J Control Release"},{"key":"313_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000330410","volume":"76","author":"K Ekstr\u00f6m","year":"2011","unstructured":"Ekstr\u00f6m K, Carlsson-Skwirut C, Ritz\u00e9n EM, Bang P. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-I alone in two brothers with growth hormone insensitivity syndrome: Effects on insulin sensitivity, body composition and linear gro. Horm Res Paediatr. 2011;76:355\u201366.","journal-title":"Horm Res Paediatr"},{"key":"313_CR36","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/cells9061516","volume":"9","author":"M Walz","year":"2020","unstructured":"Walz M, Chau L, Walz C, Sawitzky M, Ohde D, Brenmoehl J, et al. Overlap of peak growth activity and peak IGF-1 to IGFBP ratio: delayed increase of IGFBPs versus IGF-1 in serum as a mechanism to speed up and down postnatal weight gain in mice. Cells. 2020;9:1516.","journal-title":"Cells."},{"key":"313_CR37","doi-asserted-by":"publisher","first-page":"111052","DOI":"10.1016\/j.mce.2020.111052.","volume":"519","author":"M Dixit","year":"2021","unstructured":"Dixit M, Poudel SB, Yakar S. Effects of GH\/IGF axis on bone and cartilage. Mol Cell Endocrinol. 2021;519:111052. https:\/\/doi.org\/10.1016\/j.mce.2020.111052","journal-title":"Mol Cell Endocrinol"},{"key":"313_CR38","doi-asserted-by":"publisher","first-page":"19378","DOI":"10.1073\/pnas.0809223105","volume":"105","author":"E Stratikopoulos","year":"2008","unstructured":"Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A. 2008;105:19378\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"313_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11914-020-00570-x","volume":"18","author":"HL Racine","year":"2020","unstructured":"Racine HL, Serrat MA. The actions of IGF-1 in the growth plate and its role in postnatal bone elongation. Curr Osteoporos Rep. 2020;18:210\u201327. https:\/\/doi.org\/10.1007\/s11914-020-00570-x","journal-title":"Curr Osteoporos Rep"},{"key":"313_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1152\/physiolgenomics.00022.2007","volume":"30","author":"KE Govoni","year":"2007","unstructured":"Govoni KE, Seong KL, Chung YS, Behringer RR, Wergedal JE, Baylink DJ, et al. Disruption of insulin-like growth factor-I expression in type II\u03b1I collagen-expressing cells reduces bone length and width in mice. Physiol Genom. 2007;30:354\u201362.","journal-title":"Physiol Genom"},{"key":"313_CR41","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1210\/en.2008-0985","volume":"150","author":"EF Gevers","year":"2009","unstructured":"Gevers EF, Hannah MJ, Waters MJ, Robinson ICAF. Regulation of rapid signal transducer and activator of transcription-5 phosphorylation in the resting cells of the growth plate and in the liver by growth hormone and feeding. Endocrinology. 2009;150:3627\u201336.","journal-title":"Endocrinology."},{"key":"313_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ecl.2012.04.011","volume":"41","author":"A Garten","year":"2012","unstructured":"Garten A, Schuster S, Kiess W. The insulin-like growth factors in adipogenesis and obesity. Endocrinol Metab Clin North Am. 2012;41:283\u201395.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"313_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1210\/en.2018-00850","volume":"160","author":"EO List","year":"2019","unstructured":"List EO, Berryman DE, Buchman M, Parker C, Funk K, Bell S, et al. Adipocyte-Specific GH Receptor-Null (AdGHRKO) mice have enhanced insulin sensitivity with reduced liver triglycerides. Endocrinology. 2019;160:68\u201380.","journal-title":"Endocrinology."},{"key":"313_CR44","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/me.2012-1330","volume":"27","author":"EO List","year":"2013","unstructured":"List EO, Berryman DE, Funk K, Gosney ES, Jara A, Kelder B, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27:524\u201335.","journal-title":"Mol Endocrinol"},{"key":"313_CR45","doi-asserted-by":"publisher","first-page":"579909","DOI":"10.3389\/fendo.2020.579909","volume":"11","author":"A Nagarajan","year":"2020","unstructured":"Nagarajan A, Srivastava H, Jablonsky J, Sun LY. Tissue-specific GHR knockout mice: an updated review. Front Endocrinol. 2020;11:579909. https:\/\/doi.org\/10.3389\/fendo.2020.579909","journal-title":"Front Endocrinol"},{"key":"313_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fendo.2018.00035","volume":"9","author":"F Dehkhoda","year":"2018","unstructured":"Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Front Endocrinol. 2018;9:35. https:\/\/doi.org\/10.3389\/fendo.2018.00035","journal-title":"Front Endocrinol"},{"key":"313_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/TCRM.S6178","volume":"5","author":"FD Cappa","year":"2009","unstructured":"Cappa FD, Brufani C. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag. 2009;5:553\u20139.","journal-title":"Ther Clin Risk Manag"},{"key":"313_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","volume":"39","author":"GN Nguyen","year":"2021","unstructured":"Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39:47\u201355.","journal-title":"Nat Biotechnol"},{"key":"313_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/hum.2011.183","volume":"23","author":"L Wang","year":"2012","unstructured":"Wang L, Wang H, Bell P, McMenamin D, Wilson JM. Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. Hum Gene Ther. 2012;23:533\u20139.","journal-title":"Hum Gene Ther"},{"key":"313_CR50","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/onc.2017.352","volume":"37","author":"Y Chhabra","year":"2018","unstructured":"Chhabra Y, Wong HY, Nikolajsen LF, Steinocher H, Papadopulos A, Tunny KA, et al. A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation. Oncogene. 2018;37:489\u2013501.","journal-title":"Oncogene."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00313-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:03:25Z","timestamp":1655406205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00313-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1038\/s41434-022-00313-w","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"10 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}